-
1
-
-
34547651880
-
AACE Guidelines. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly
-
AACE Guidelines. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Practice 2004 10 214-225.
-
(2004)
Endocrine Practice
, vol.10
, pp. 214-225
-
-
-
2
-
-
4744348959
-
Acromegaly
-
edn 2 ch. 11, pp, Ed. S Melmed, Massachusetts: Blackwell Science Inc
-
Melmed S. Acromegaly. In The Pituitary, edn 2 (ch. 11), pp 419-454. Ed. S Melmed, Massachusetts: Blackwell Science Inc, 2002.
-
(2002)
The Pituitary
, pp. 419-454
-
-
Melmed, S.1
-
4
-
-
33750069148
-
Is there still a role for radiotherapy in acromegaly?
-
Monson JP. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology 2006 83 269-273.
-
(2006)
Neuroendocrinology
, vol.83
, pp. 269-273
-
-
Monson, J.P.1
-
6
-
-
0034836491
-
Efficacy of radiotherapy in normalizing serum IGF-I. acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly
-
Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G & Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I. acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clinical Endocrinology 2001 55 183-189.
-
(2001)
Clinical Endocrinology
, vol.55
, pp. 183-189
-
-
Epaminonda, P.1
Porretti, S.2
Cappiello, V.3
Beck-Peccoz, P.4
Faglia, G.5
Arosio, M.6
-
7
-
-
4544253068
-
Pharmacological therapy for acromegaly. A critical review
-
Muller AF & van der Lely AJ. Pharmacological therapy for acromegaly. A critical review. Drugs 2004 16 1817-1838.
-
(2004)
Drugs
, vol.16
, pp. 1817-1838
-
-
Muller, A.F.1
van der Lely, A.J.2
-
8
-
-
0029885384
-
Treatment of prolactin-secreting macroadenoma with the once-weekly dopamine agonist cabergoline
-
Biller BMK, Molitch ME, Vance ML, Baker Cannistrato K, Davis KR, Simons JA, Schoenfelder JR & Klibanski A. Treatment of prolactin-secreting macroadenoma with the once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism 1996 81 2338-2343.
-
(1996)
Journal of Clinical Endocrinology and Metabolism
, vol.81
, pp. 2338-2343
-
-
Biller, B.M.K.1
Molitch, M.E.2
Vance, M.L.3
Baker Cannistrato, K.4
Davis, K.R.5
Simons, J.A.6
Schoenfelder, J.R.7
Klibanski, A.8
-
9
-
-
0031792509
-
Cabergoline in the treatment of acromegaly: A study in 64 patients
-
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
-
(1998)
Journal of Clinical Endocrinology and Metabolism
, vol.83
, pp. 374-378
-
-
Abs, R.1
Verhelst, J.2
Maiter, D.3
Van Acker, K.4
Nobels, F.5
Coolens, J.L.6
Mahler, C.7
Beckers, A.8
-
10
-
-
23844540615
-
Long-acting somatostatin analog therapy of acromegaly: A meta-analysis
-
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
-
(2005)
Journal of Clinical Endocrinology and Metabolism
, vol.90
, pp. 4465-4473
-
-
Freda, P.U.1
Katznelson, L.2
van der Lely, A.J.3
Reyes, C.M.4
Zhao, S.5
Rabinowitz, D.6
-
11
-
-
0033672781
-
Slow release lanreotide in the treatment of acromegaly: A study of 66 patients
-
Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J & Pagani G. Slow release lanreotide in the treatment of acromegaly: a study of 66 patients. European Journal of Endocrinology 2000 143 577-584.
-
(2000)
European Journal of Endocrinology
, vol.143
, pp. 577-584
-
-
Verhelst, J.A.1
Pedroncelli, A.M.2
Abs, R.3
Montini, M.4
Vandeweghe, M.V.5
Albani, G.6
Maiter, D.7
Pagani, M.D.8
Legros, J.J.9
Gianola, D.10
Bex, M.11
Poppe, K.12
Mockel, J.13
Pagani, G.14
-
12
-
-
0028864383
-
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
-
Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly, Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
-
(1995)
Journal of Clinical Endocrinology and Metabolism
, vol.80
, pp. 3267-3272
-
-
Stewart, P.M.1
Kane, K.F.2
Stewart, S.E.3
Lancranjan, I.4
Sheppard, M.C.5
-
13
-
-
0029922510
-
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group
-
Giusti M, Gussoni G, Cuttica CM & Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
-
(1996)
Journal of Clinical Endocrinology and Metabolism
, vol.81
, pp. 2089-2097
-
-
Giusti, M.1
Gussoni, G.2
Cuttica, C.M.3
Giordano, G.4
-
15
-
-
0033291744
-
Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group
-
Lancranjan I & Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999 1 105-114.
-
(1999)
Pituitary
, vol.1
, pp. 105-114
-
-
Lancranjan, I.1
Atkinson, A.B.2
-
16
-
-
4744375607
-
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
-
Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R & Maiter D. Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology 2005 151 317-324.
-
(2005)
European Journal of Endocrinology
, vol.151
, pp. 317-324
-
-
Alexopoulou, O.1
Abrams, P.2
Verhelst, J.3
Poppe, K.4
Velkeniers, B.5
Abs, R.6
Maiter, D.7
-
17
-
-
0035944825
-
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
-
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
-
(2001)
Lancet
, vol.358
, pp. 1754-1759
-
-
van der Lely, A.J.1
Hutson, R.K.2
Trainer, P.J.3
Besser, G.M.4
Barkan, A.L.5
Katznelson, L.6
Klibanski, A.7
Herman-Bonert, V.8
Melmed, S.9
Vance, M.L.10
Freda, P.U.11
Stewart, P.M.12
Friend, K.E.13
Clemmons, D.R.14
Johannsson, G.15
Stavrou, S.16
Cook, D.M.17
Phillips, L.S.18
Strasburger, C.J.19
Hackett, S.20
Zib, K.A.21
Davis, R.J.22
Scarlett, J.A.23
Thorner, M.O.24
more..
-
18
-
-
17744392005
-
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
-
Selvarajah D, Webster J, Ross R & Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology 2005 152 569-574.
-
(2005)
European Journal of Endocrinology
, vol.152
, pp. 569-574
-
-
Selvarajah, D.1
Webster, J.2
Ross, R.3
Newell-Price, J.4
-
19
-
-
18744389775
-
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
-
Feenstra J, de Herder WW ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 13 1644-1646.
-
(2005)
Lancet
, vol.13
, pp. 1644-1646
-
-
Feenstra, J.1
de Herder, W.W.2
ten Have, S.M.3
van den Beld, A.W.4
Feelders, R.A.5
Janssen, J.A.6
van der Lely, A.J.7
-
20
-
-
10744231363
-
Lewis I, Weckbecker G, Krahnke T, Hofland LJ & Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
-
van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW. Lewis I, Weckbecker G, Krahnke T, Hofland LJ & Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2004 89 638-645.
-
(2004)
Journal of Clinical Endocrinology and Metabolism
, vol.89
, pp. 638-645
-
-
van der Hoek, J.1
de Herder, W.W.2
Feelders, R.A.3
van der Lely, A.J.4
Uitterlinden, P.5
Boerlin, V.6
Bruns, C.7
Poon, K.W.8
-
21
-
-
22744440925
-
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
-
Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 2005 153 135-141.
-
(2005)
European Journal of Endocrinology
, vol.153
, pp. 135-141
-
-
Jaquet, P.1
Gunz, G.2
Saveanu, A.3
Dufour, H.4
Taylor, J.5
Dong, J.6
Kim, S.7
Moreau, J.P.8
Enjalbert, A.9
Culler, M.D.10
-
22
-
-
0034493775
-
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration
-
Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP & Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology 2000 53 719-724.
-
(2000)
Clinical Endocrinology
, vol.53
, pp. 719-724
-
-
Jenkins, P.J.1
Akker, S.2
Chew, S.L.3
Besser, G.M.4
Monson, J.P.5
Grossman, A.B.6
-
23
-
-
0034123755
-
Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: Clinical implications
-
Caron P, Tabarin A, Cogne M, Chanson P & Jaquet P. Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: clinical implications. European Journal of Endocrinology 2000 142 565-571.
-
(2000)
European Journal of Endocrinology
, vol.142
, pp. 565-571
-
-
Caron, P.1
Tabarin, A.2
Cogne, M.3
Chanson, P.4
Jaquet, P.5
-
24
-
-
33747374573
-
Spanish-Portuguese Multicentre Autogel Study Group on acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
-
Lucas T & Astorga R. Spanish-Portuguese Multicentre Autogel Study Group on acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clinical Endocrinology 2006 65 320-326.
-
(2006)
Clinical Endocrinology
, vol.65
, pp. 320-326
-
-
Lucas, T.1
Astorga, R.2
-
25
-
-
0037335063
-
Sandostatin LAR in acromegaly: A 6-week injection interval suppresses GH secretion as effectively as a 4-week interval
-
Biermasz NR, van den Oever NC, Frolich M, Arias AM, Srnit JW, Romijn JA & Roelfsema F. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical Endocrinology 2003 58 288-295.
-
(2003)
Clinical Endocrinology
, vol.58
, pp. 288-295
-
-
Biermasz, N.R.1
van den Oever, N.C.2
Frolich, M.3
Arias, A.M.4
Srnit, J.W.5
Romijn, J.A.6
Roelfsema, F.7
-
26
-
-
4143086978
-
Systematic dose-extension of octreotide LAR: The importance of individual tailoring of treatment in patients with acromegaly
-
Turner HE, Thornton-Jones VA & Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clinical Endocrinology 2004 61 224-231.
-
(2004)
Clinical Endocrinology
, vol.61
, pp. 224-231
-
-
Turner, H.E.1
Thornton-Jones, V.A.2
Wass, J.A.3
-
27
-
-
11144357696
-
Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers
-
Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Valles J, Cherif-Cheikh R, Torres ML, Bismuth F & Montes M. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology 2004 56 471-476.
-
(2004)
Journal of Pharmacy and Pharmacology
, vol.56
, pp. 471-476
-
-
Antonijoan, R.M.1
Barbanoj, M.J.2
Cordero, J.A.3
Peraire, C.4
Obach, R.5
Valles, J.6
Cherif-Cheikh, R.7
Torres, M.L.8
Bismuth, F.9
Montes, M.10
-
28
-
-
0032922259
-
Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR)
-
Stewart PM, Stewart SE, Clark PM & Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology 1999 50 295-299.
-
(1999)
Clinical Endocrinology
, vol.50
, pp. 295-299
-
-
Stewart, P.M.1
Stewart, S.E.2
Clark, P.M.3
Sheppard, M.C.4
-
29
-
-
0034974291
-
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
-
Colao A & Ferone D. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
-
(2001)
Journal of Clinical Endocrinology and Metabolism
, vol.86
, pp. 2779-2786
-
-
Colao, A.1
Ferone, D.2
-
30
-
-
33745794539
-
Acromegaly: Molecular expression of somatostatin receptors subtypes and treatment outcome
-
Bronstein MD. Acromegaly: molecular expression of somatostatin receptors subtypes and treatment outcome. Frontiers of Hormone Research 2006 35 129-134.
-
(2006)
Frontiers of Hormone Research
, vol.35
, pp. 129-134
-
-
Bronstein, M.D.1
-
32
-
-
23244442834
-
Treatment of acromegaly with octreotide -LAR extensive experience in a Brzilian institution
-
Jallad RS, Musolino NR, Salgado LR & Bronstein MD. Treatment of acromegaly with octreotide -LAR extensive experience in a Brzilian institution. Clinical Endocrinology 2005 63 168-175.
-
(2005)
Clinical Endocrinology
, vol.63
, pp. 168-175
-
-
Jallad, R.S.1
Musolino, N.R.2
Salgado, L.R.3
Bronstein, M.D.4
-
33
-
-
0034974291
-
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
-
Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranj an I & Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
-
(2001)
Journal of Clinical Endocrinology and Metabolism
, vol.86
, pp. 2779-2786
-
-
Colao, A.1
Ferone, D.2
Marzullo, P.3
Cappabianca, P.4
Cirillo, S.5
Boerlin, V.6
Lancranj an, I.7
Lombardi, G.8
|